In vivo expressed biologics for infectious disease prophylaxis: rapid delivery of DNA-based antiviral antibodies

References

• Smith KF, Goldberg M, Rosenthal S, et al. Global rise in human infectious disease outbreaks. J Roy Soc Interface. 2014;11:20140950. doi: 10.1098/rsif.2014.0950
   PubMed Web of Science ®Google Scholar
• Findlater A, Bogoch II. Human mobility and the global spread of infectious diseases: a focus on air travel. Trends Parasitol. 2018;34:772–783. doi: 10.1016/j.pt.2018.07.004
   PubMed Web of Science ®Google Scholar
• Eisinger RW, Dieffenbach CW, Fauci AS. HIV viral load and transmissibility of HIV infection. Jama. 2019;321:451–452. doi: 10.1001/jama.2018.21167
   PubMed Web of Science ®Google Scholar
• Delamater PL, Street EJ, Leslie TF, et al. Complexity of the basic reproduction number (R0) - volume 25, number 1—January 2019 - emerging infectious diseases journal - CDC. Emerg Infect Dis. 2019;25:1–4. doi: 10.3201/eid2501.171901
   PubMed Web of Science ®Google Scholar
• Bloom DE, Black S, Rappuoli R. Emerging infectious diseases: A proactive approach. Proc National Acad Sci. 2017;114:4055–4059. doi: 10.1073/pnas.1701410114
   PubMed Web of Science ®Google Scholar
• Wolfe DN, Zarrabian AG, Disbrow GL, et al. Progress towards a vaccine against Ebola to meet emergency medical countermeasure needs. Vaccine. 2019;37:7178–7182. doi: 10.1016/j.vaccine.2017.10.111
   PubMed Web of Science ®Google Scholar
• Broadbent AJ, Subbarao K. Influenza virus vaccines: lessons from the 2009 H1N1 pandemic. Curr Opin Virol. 2011;1:254–262. doi: 10.1016/j.coviro.2011.08.002
   PubMed Web of Science ®Google Scholar
• Prevention C for DC and. Vaccine Testing and the Approval Process. (2020).
   Google Scholar
• Lurie N, Saville M, Hatchett R, et al. Developing covid-19 vaccines at pandemic speed. New Engl J Med. 2020;382:1969–1973. doi: 10.1056/NEJMp2005630
   PubMed Web of Science ®Google Scholar
• Everts M, Cihlar T, Bostwick JR, et al. Accelerating drug development: antiviral therapies for emerging viruses as a model. Annu Rev Pharmacol. 2016;57:1–15.
   Google Scholar
• Cao B, Wang Y, Wen D, et al. A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. New Engl J Med. 2020;382:1787–1799. doi:10.1056/nejmoa2001282.
   PubMed Web of Science ®Google Scholar
• Tu Y-F, Chien C-S, Yarmishyn AA, et al. A review of SARS-CoV-2 and the ongoing clinical trials. Int J Mol Sci. 2020;21:2657. doi: 10.3390/ijms21072657
   PubMed Web of Science ®Google Scholar
• Thorlund K, Dron L, Park J, et al. A real-time dashboard of clinical trials for COVID-19. Lancet Digital Heal. 2020;2:e286–e287. doi:10.1016/s2589-7500(20)30086-8.
   PubMedGoogle Scholar
• Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395:1569–1578. doi:10.1016/s0140-6736(20)31022-9.
   PubMed Web of Science ®Google Scholar
• Pelfrene E, Mura M, Sanches AC, et al. Monoclonal antibodies as anti-infective products: a promising future? Clin Microbiol Infec. 2018;25:60–64. doi: 10.1016/j.cmi.2018.04.024
   PubMed Web of Science ®Google Scholar
• Salazar G, Zhang N, Fu T-M, et al. Antibody therapies for the prevention and treatment of viral infections. Npj Vaccines. 2017;2:19. doi: 10.1038/s41541-017-0019-3
   PubMed Web of Science ®Google Scholar
• Marston HD, Paules CI, Fauci AS. Monoclonal antibodies for emerging infectious diseases — borrowing from history. New Engl J Med. 2018;378:1469–1472. doi: 10.1056/NEJMp1802256
   PubMed Web of Science ®Google Scholar
• Froude JW, Stiles BG, Pelat T, et al. Antibodies for biodefense. Mabs. 2011;3:517–527. doi: 10.4161/mabs.3.6.17621
   PubMed Web of Science ®Google Scholar
• McTamney P. Utilizing the human body as a bioreactor: direct comparison of in vivo expressed biologics (IVEB) delivery platforms. Antibodies as drugs: from B cell biology to new treatments; 2020 February; Santa Fe, NM; 2020.
   Google Scholar
• Wang X, Mathieu M, Brezski RJ. Igg Fc engineering to modulate antibody effector functions. Protein Cell. 2018;9:63–73. doi: 10.1007/s13238-017-0473-8
   PubMed Web of Science ®Google Scholar
• Smatti MK, Thani AAA, Yassine HM. Viral-induced enhanced disease illness. Front Microbiol. 2018;9:2991. doi: 10.3389/fmicb.2018.02991
   PubMed Web of Science ®Google Scholar
• Tseng C-T, Sbrana E, Iwata-Yoshikawa N, et al. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. Plos One. 2012;7:e35421. doi: 10.1371/journal.pone.0035421
   PubMed Web of Science ®Google Scholar
• Liu L, Wei Q, Lin Q, et al. Anti–spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. Jci Insight. 2019;4:e123158. doi: 10.1172/jci.insight.123158
   PubMed Web of Science ®Google Scholar
• Hummel J, Pagkaliwangan M, Gjoka X, et al. Modeling the downstream processing of monoclonal antibodies reveals cost advantages for continuous methods for a broad range of manufacturing scales. Biotechnol J. 2019;14:1700665. doi: 10.1002/biot.201700665
   Web of Science ®Google Scholar
• Shukla AA, Wolfe LS, Mostafa SS, et al. Evolving trends in mAb production processes. Bioeng Transl Medicine. 2017;2:58–69. doi: 10.1002/btm2.10061
   PubMed Web of Science ®Google Scholar
• Kelley B. Developing therapeutic monoclonal antibodies at pandemic pace. Nat Biotechnol. 2020;38:540–545. doi: 10.1038/s41587-020-0512-5
   PubMed Web of Science ®Google Scholar
• Hernandez I, Bott SW, Patel AS, et al. Pricing of monoclonal antibody therapies: higher if used for cancer? Am J Managed Care. 2018;24:109–112.
   PubMed Web of Science ®Google Scholar
• Greenwood B. The contribution of vaccination to global health: past, present and future. Philos Trans R Soc B Biol Sci. 2014;369:20130433. doi: 10.1098/rstb.2013.0433
   PubMed Web of Science ®Google Scholar
• Mahy M, Stover J, Stanecki K, et al. Estimating the impact of antiretroviral therapy: regional and global estimates of life-years gained among adults. Sex Transm Infect. 2010;86:ii67.
   PubMed Web of Science ®Google Scholar
• Bedford J, Farrar J, Ihekweazu C, et al. A new twenty-first century science for effective epidemic response. Nature. 2019;575:130–136. doi: 10.1038/s41586-019-1717-y
   PubMed Web of Science ®Google Scholar
• Corti D, Lanzavecchia A. Broadly neutralizing antiviral antibodies. Annu Rev Immunol. 2013;31:705–742. doi: 10.1146/annurev-immunol-032712-095916
   PubMed Web of Science ®Google Scholar
• Patel A, Bah MA, Weiner DB. In vivo delivery of nucleic acid-encoded monoclonal antibodies. Biodrugs. 2020;34:273–293. doi: 10.1007/s40259-020-00412-3
   PubMed Web of Science ®Google Scholar
• Wang D, Tai PW, Gao G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discovery. 2019;18:358–378. doi:10.1038/s41573-019-0012-9.
   PubMed Web of Science ®Google Scholar
• Priddy FH, Lewis DJM, Gelderblom HC, et al. Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial. Lancet Hiv. 2019;6:e230–e239. doi: 10.1016/S2352-3018(19)30003-7
   PubMed Web of Science ®Google Scholar
• Casazza JP. Durable HIV-1 antibody production in humans after AAV8-mediated gene transfer. Conference on retroviruses and opportunistic infections; 2020 March; Boston, MA; 2020.
   Google Scholar
• Gardner MR, Fetzer I, Kattenhorn LM, et al. Anti-drug antibody responses impair prophylaxis mediated by AAV-delivered HIV-1 broadly neutralizing antibodies. Mol Ther. 2019;27:650–660. doi:10.1016/j.ymthe.2019.01.004.
   PubMed Web of Science ®Google Scholar
• Martinez-Navio JM, Fuchs SP, Pantry SN, et al. Adeno-associated virus delivery of anti-HIV monoclonal antibodies can drive long-term virologic suppression. Immunity. 2019;50:567–575.e5. doi: 10.1016/j.immuni.2019.02.005
   PubMed Web of Science ®Google Scholar
• Kowalski PS, Rudra A, Miao L, et al. Delivering the messenger: advances in technologies for therapeutic mRNA delivery. Mol Ther. 2019;27:710–728. doi: 10.1016/j.ymthe.2019.02.012
   PubMed Web of Science ®Google Scholar
• Schlake T, Thran M, Fiedler K, et al. Messenger RNA, a novel avenue to antibody therapy? Mol Ther. 2019;27:773–784. doi: 10.1016/j.ymthe.2019.03.002
   PubMed Web of Science ®Google Scholar
• Thran M, Mukherjee J, Pönisch M, et al. mRNA mediates passive vaccination against infectious agents, toxins, and tumors. Embo Mol Med. 2017;9:1434–1447. doi: 10.15252/emmm.201707678
   PubMed Web of Science ®Google Scholar
• Pardi N, Secreto AJ, Shan X, et al. Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge. Nat Commun. 2017;8:ncomms14630. doi: 10.1038/ncomms14630
   Web of Science ®Google Scholar
• Sabnis S, Kumarasinghe ES, Salerno T, et al. A novel amino lipid series for mRNA delivery: improved endosomal escape and sustained pharmacology and safety in non-human primates. Mol Ther. 2018;26:1509–1519. doi: 10.1016/j.ymthe.2018.03.010
   PubMed Web of Science ®Google Scholar
• Sardesai NY, Weiner DB. Electroporation delivery of DNA vaccines: prospects for success. Curr Opin Immunol. 2011;23:421–429. doi: 10.1016/j.coi.2011.03.008
   PubMed Web of Science ®Google Scholar
• Algazi AP, Bhatia S, Agarwala SS, et al. Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients. Ann Oncol. 2020;31:532–540. doi: 10.1016/j.annonc.2019.12.008
   PubMed Web of Science ®Google Scholar
• Aihara H, Miyazaki J. Gene transfer into muscle by electroporation in vivo. Nat Biotechnol. 1998;16:867–870. doi: 10.1038/nbt0998-867
   PubMed Web of Science ®Google Scholar
• Mir L, Bureau M, Gehl J, et al. High-efficiency gene transfer into skeletal muscle mediated by electric pulses. Proc Natl Acad Sci. 1999;96:4262–4267. doi: 10.1073/pnas.96.8.4262
   PubMed Web of Science ®Google Scholar
• Rizzuto G, Cappelletti M, Maione D, et al. Efficient and regulated erythropoietin production by naked DNA injection and muscle electroporation. Proc Natl Acad Sci. 1999;96:6417–6422. doi: 10.1073/pnas.96.11.6417
   PubMed Web of Science ®Google Scholar
• Tjelle TE, Corthay A, Lunde E, et al. Monoclonal antibodies produced by muscle after plasmid injection and electroporation. Mol Ther. 2004;9:328–336. doi: 10.1016/j.ymthe.2003.12.007
   PubMed Web of Science ®Google Scholar
• Perez N, Bigey P, Scherman D, et al. Regulatable systemic production of monoclonal antibodies by in vivo muscle electroporation. Genet Vaccines Ther. 2004;2:1–5. doi: 10.1186/1479-0556-2-2
   PubMedGoogle Scholar
• Rosazza C, Meglic S, Zumbusch A, et al. Gene electrotransfer: a mechanistic perspective. Curr Gene Ther. 2016;16:98–129. doi: 10.2174/1566523216666160331130040
   PubMed Web of Science ®Google Scholar
• Khan AS, Smith LC, Abruzzese RV, et al. Optimization of electroporation parameters for the intramuscular delivery of plasmids in pigs. DNA Cell Biol. 2003;22:807–814. doi: 10.1089/104454903322625019
   PubMed Web of Science ®Google Scholar
• Schertzer JD, Plant DR, Lynch GS. Optimizing plasmid-based gene transfer for investigating skeletal muscle structure and function. Mol Ther. 2006;13:795–803. doi: 10.1016/j.ymthe.2005.09.019
   PubMed Web of Science ®Google Scholar
• Molnar MJ, Gilbert R, Lu Y, et al. Factors Influencing the efficacy, longevity, and safety of electroporation-assisted plasmid-based gene transfer into mouse muscles. Mol Ther. 2004;10:447–455. doi: 10.1016/j.ymthe.2004.06.642
   PubMed Web of Science ®Google Scholar
• Bureau MF, Naimi S, Ibad TR, et al. Intramuscular plasmid DNA electrotransfer. Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression. 2004;1676:138–148. doi: 10.1016/j.bbaexp.2003.11.005
   PubMed Web of Science ®Google Scholar
• Demonbreun AR, McNally EM. DNA electroporation, isolation and Imaging of Myofibers. J Visualized Exp. 2015;106:e53551.
   Google Scholar
• Wang X-D, Tang J-G, Xie X, et al. A comprehensive study of optimal conditions for naked plasmid DNA transfer into skeletal muscle by electroporation. J Gene Med. 2005;7:1235–1245. doi: 10.1002/jgm.765
   PubMed Web of Science ®Google Scholar
• Lesbordes J-CC, Bordet T, Haase G, et al. In vivo electrotransfer of the cardiotrophin-1 gene into skeletal muscle slows down progression of motor neuron degeneration in pmn mice. Hum Mol Genet. 2002;11:1615–1625. doi: 10.1093/hmg/11.14.1615
   PubMed Web of Science ®Google Scholar
• Yamazaki T, Nagashima M, Ninomiya D, et al. Passive immune-prophylaxis against influenza virus infection by the expression of neutralizing anti-hemagglutinin monoclonal antibodies from plasmids. Jpn J Infect Dis. 2011;64:40–49.
   PubMed Web of Science ®Google Scholar
• Flingai S, Plummer EM, Patel A, et al. Protection against dengue disease by synthetic nucleic acid antibody prophylaxis/immunotherapy. Sci Rep. 2015;5:12616. doi: 10.1038/srep12616
   PubMed Web of Science ®Google Scholar
• Elliott ST, Kallewaard NL, Benjamin E, et al. DMAb inoculation of synthetic cross reactive antibodies protects against lethal influenza A and B infections. npj Vaccines. 2017;2:18. doi: 10.1038/s41541-017-0020-x
   PubMed Web of Science ®Google Scholar
• Muthumani K, Block P, Flingai S, et al. Rapid and long-term immunity elicited by DNA-encoded antibody prophylaxis and DNA vaccination against chikungunya virus. J Infect Dis. 2016;214:369–378. doi: 10.1093/infdis/jiw111
   PubMed Web of Science ®Google Scholar
• Andrews CD, Luo Y, Sun M, et al. In vivo production of monoclonal antibodies by gene transfer via electroporation protects against lethal influenza and Ebola infections. Mol Ther Methods Clin Dev. 2017;7:74–82. doi: 10.1016/j.omtm.2017.09.003
   PubMed Web of Science ®Google Scholar
• Patel A, Park DH, Davis CW, et al. In vivo delivery of synthetic human DNA-encoded monoclonal antibodies protect against Ebolavirus infection in a mouse model. Cell Rep. 2018;25:1982–1993.e4. doi: 10.1016/j.celrep.2018.10.062
   PubMed Web of Science ®Google Scholar
• Choi H, Kudchodkar SB, Reuschel EL, et al. Synthetic nucleic acid antibody prophylaxis confers rapid and durable protective immunity against Zika virus challenge. Hum Vaccin Immunother. 2019;16(4):907–918.
   Web of Science ®Google Scholar
• Esquivel RN, Patel A, Kudchodkar SB, et al. In vivo delivery of a DNA-encoded monoclonal antibody protects non-human primates against Zika virus. Mol Ther. 2019;27:974–985. doi: 10.1016/j.ymthe.2019.03.005
   PubMed Web of Science ®Google Scholar
• Liu Y, Cao W, Sun M, et al. AAABroadly neutralizing antibodies for HIV-1: efficacies, challenges and opportunities. Emerg Microbes Infec. 2020;9:194–206. doi: 10.1080/22221751.2020.1713707
   PubMed Web of Science ®Google Scholar
• Caskey M. Broadly neutralizing antibodies for the treatment and prevention of HIV infection. Curr Opin Hiv Aids. 2020;15:49–55. doi: 10.1097/COH.0000000000000600
   PubMed Web of Science ®Google Scholar
• Klein F, Halper-Stromberg A, Horwitz JA, et al. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature. 2012;492:118–122. doi: 10.1038/nature11604
   PubMed Web of Science ®Google Scholar
• Kong R, Louder MK, Wagh K, et al. Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes. J Virol. 2015;89:2659–2671. doi: 10.1128/JVI.03136-14
   PubMed Web of Science ®Google Scholar
• Wise MC, Xu Z, Tello-Ruiz E, et al. In vivo delivery of synthetic DNA-encoded antibodies induces broad HIV-1-neutralizing activity. J Clin Invest. 2019;130:827–837. doi: 10.1172/JCI132779
   Web of Science ®Google Scholar
• Mulangu S, Dodd LE, Davey Jr RT, et al. A Randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med. 2019;381:2293–2303. doi: 10.1056/NEJMoa1910993
   PubMed Web of Science ®Google Scholar
• Wang C, Li W, Drabek D, et al. A human monoclonal antibody blocking SARS-CoV-2 infection. Nat Commun. 2020;11:2251. doi: 10.1038/s41467-020-16256-y
   PubMed Web of Science ®Google Scholar
• Wrapp D, Vlieger DD, Corbett KS, et al. Structural basis for potent neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies. Cell. 2020;181:1004–1015.e15. doi:10.1016/j.cell.2020.04.031.
   PubMed Web of Science ®Google Scholar
• Ye Q, Wang B, Mao J. The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19. J Infection. 2020;80:607–613. doi:10.1002/jmv.25897 doi: 10.1016/j.jinf.2020.03.037
   PubMed Web of Science ®Google Scholar
• Giambenedetto SD, Ciccullo A, Borghetti A, et al. Off-label Use of tocilizumab in patients with SARS-CoV-2 infection. J Med Virol. 2020. doi:10.1002/jmv.25897.
   PubMedGoogle Scholar
• Cavalli G, Luca GD, Campochiaro C, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol. 2020;2:e325–e331. doi: 10.1016/S2665-9913(20)30127-2
   PubMedGoogle Scholar
• Luo P, Liu Y, Qiu L, et al. Tocilizumab treatment in COVID-19: A single center experience. J Med Virol. 2020;92:814–818. doi:10.1002/jmv.25801.
   PubMed Web of Science ®Google Scholar
• Tjelle TE, Salte R, Mathiesen I, et al. A novel electroporation device for gene delivery in large animals and humans. Vaccine. 2006;24:4667–4670. doi: 10.1016/j.vaccine.2005.08.068
   PubMed Web of Science ®Google Scholar
• Hollevoet K, Vleeschauwer SD, Smidt ED, et al. Bridging the clinical gap for DNA-based antibody therapy through translational studies in sheep. Hum Gene Ther. 2019;30:1431–1443. doi: 10.1089/hum.2019.128
   PubMed Web of Science ®Google Scholar
• Chirmule N, Jawa V, Meibohm B. Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy. Aaps J. 2012;14:296–302. doi: 10.1208/s12248-012-9340-y
   PubMed Web of Science ®Google Scholar